Chinese General Practice ›› 2020, Vol. 23 ›› Issue (3): 362-368.DOI: 10.12114/j.issn.1007-9572.2019.00.251
• Monographic Research • Previous Articles Next Articles
Published:
2020-01-20
Online:
2020-01-20
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2019.00.251
[1]SOMMER F,B?CKHED F.The gut microbiota——masters of host development and physiology[J].Nat Rev Micro,2013,11(4):227-238.DOI:10.1038/nrmicro2974. [2]SáNCHEZ B,DELGADO S,BLANCO-MíGUEZ A,et al.Probiotics,gut microbiota,and their influence on host health and disease[J].Mol Nutr Food Res,2017,61(1).[Epub ahead of print].DOI:10.1002/mnfr.201600240. [3]MORELLI L,CAPURSO L.FAO/WHO guidelines on probiotics:10 years later[J].J Clin Gastroenterol,2012,46(Suppl):S1-2.DOI:10.1097/MCG.0b013e318269fdd5. [4]KORETZ R L.Probiotics in gastroenterology:how pro is the evidence in adults?[J].Am J Gastroenterol,2018,113(8):1125-1136.DOI:10.1038/s41395-018-0138-0. [5]LIU Y Y,TRAN D Q,RHOADS J M.Probiotics in disease prevention and treatment[J].J Clin Pharmacol,2018,58(Suppl 10):S164-179.DOI:10.1002/jcph.1121. [6]VALDOVINOS M A,MONTIJO E,ABREU A T,et al.The Mexican consensus on probiotics in gastroenterology[J].Rev Gastroenterol Mex,2017,82(2):156-178.DOI:10.1016/j.rgmx.2016.08.004. [7]袁莉娟,刘爱民,李艺,等.微生态制剂的应用研究进展[J].临床合理用药杂志,2018,11(15):178-181.DOI:10.15887/j.cnki.13-1389/r.2018.15.088. YUAN L J,LIU A M,LI Y,et al.Application and research progress of microecologics[J].Chinese Journal of Clinical Rational Drug Use,2018,11(15):178-181.DOI:10.15887/j.cnki.13-1389/r.2018.15.088. [8]GUERRANT R L,VAN GILDER T,STEINER T S,et al.Practice guidelines for the management of infectious diarrhea[J].Clin Infect Dis,2001,32(3):331-351.DOI:10.1086/318514. [9]SURAWICZ C M.Mechanisms of diarrhea[J].Curr Gastroenterol Rep,2010,12(4):236-241.DOI:10.1007/s11894-010-0113-4. [10]孙笑非,温俊.益生菌调节肠道菌群的作用机制及研究进展[J].饲料研究,2010(4):56-58.DOI:10.13557/j.cnki.issn1002-2813.2010.04.020. [11]DICKINSON B,SURAWICZ C M.Infectious diarrhea:an overview[J].Curr Gastroenterol Rep,2014,16(8):399.DOI:10.1007/s11894-014-0399-8. [12]ANAND S,MANDAL S,PATIL P,et al.Pathogen-induced secretory diarrhea and its prevention[J].Eur J Clin Microbiol Infect Dis,2016,35(11):1721-1739.DOI:10.1007/s10096-016-2726-5. [13]GUARINO A,ALBANO F,ASHKENAZI S,et al.European Society for Paediatric Gastroenterology,Hepatology,and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe:executive summary[J].J Pediatr Gastroenterol Nutr,2008,46(5):619-621.DOI:10.1097/MPG.0b013e31816e219e. [14]WILKINS T,SEQUOIA J.Probiotics for gastrointestinal conditions:a summary of the evidence[J].Am Fam Physician,2017,96(3):170-178. [15]HILL C,GUARNER F,REID G,et al.The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J].Nat Rev Gastroenterol Hepatol,2014,11(8):506-514.DOI:10.1038/nrgastro.2014.66. [16]LEE H J,CHOI J K,RYU H S,et al.Therapeutic modulation of gut microbiota in functional bowel disorders[J].J Neurogastroenterol Motil,2017,23(1):9-19.DOI:10.5056/jnm16124. [17]BRON P A,KLEEREBEZEM M,BRUMMER R J,et al.Can probiotics modulate human disease by impacting intestinal barrier function?[J].Br J Nutr,2017,117(1):93-107.DOI:10.1017/S0007114516004037. [18]BUTEL M J.Probiotics,gut microbiota and health[J].Med Mal Infect,2014,44(1):1-8.DOI:10.1016/j.medmal.2013.10.002. [19]SENOK A C,ISMAEEL A Y,BOTTA G A.Probiotics:facts and myths[J].Clin Microbiol Infect,2005,11(12):958-966.DOI:10.1111/j.1469-0691.2005.01228.x. [20]OELSCHLAEGER T A.Mechanisms of probiotic actions——a review[J].Int J Med Microbiol,2010,300(1):57-62.DOI:10.1016/j.ijmm.2009.08.005. [21]ABRAHAM B P,QUIGLEY E M M.Probiotics in inflammatory bowel disease[J].Gastroenterol Clin North Am,2017,46(4):769-782.DOI:10.1016/j.gtc.2017.08.003. [22]SCARPELLINI E,CAZZATO A,LAURITANO C,et al.Probiotics:which and when?[J].Dig Dis,2008,26(2):175-182.DOI:10.1159/000116776. [23]SáNCHEZ B,DE LOS REYES-GAVILáN C G,MARGOLLES A,et al.Probiotic fermented milks:present and future[J].International Journal of Dairy Technology,2009,62(4):472-483.DOI:10.1111/j.1471-0307.2009.00528.x. [24]SZAJEWSKA H,KOLODZIEJ M.Systematic review with meta-analysis:Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults[J].Aliment Pharmacol Ther,2015,42(10):1149-1157.DOI:10.1111/apt.13404. [25]BEGOVIC B,AHMEDTAGIC S,CALKIC L,et al.Open clinical trial on using nifuroxazide compared to probiotics in treating acute diarrhoeas in adults[J].Mater Sociomed,2016,28(6):454-458.DOI:10.5455/msm.2016.28.454-458. [26]SASAKI Y,MURAKAMI Y,ZAI H,et al.Effect of antibiotics for infectious diarrhea on the duration of hospitalization:a retrospective cohort study at a single center in Japan from 2012 to 2015[J].J Infect Chemother,2018,24(1):59-64.DOI:10.1016/j.jiac.2017.09.004. [27]SHARIF A,KASHANI H H,NASRI E,et al.The role of probiotics in the treatment of dysentery:a randomized double-blind clinical trial[J].Probiotics Antimicrob Proteins,2017,9(4):380-385.DOI:10.1007/s12602-017-9271-0. [28]BAE J M.Prophylactic efficacy of probiotics on travelers' diarrhea:an adaptive meta-analysis of randomized controlled trials[J].Epidemiol Health,2018,40:e2018043.DOI:10.4178/epih.e2018043. [29]MCFARLAND L V,GOH S.Are probiotics and prebiotics effective in the prevention of travellers' diarrhea:a systematic review and meta-analysis[J].Travel Med Infect Dis,2019,27:11-19.DOI:10.1016/j.tmaid.2018.09.007. [30]EVANS D P.Non-pharmacotherapeutic interventions in travellers diarrhoea(TD)[J].J Travel Med,2018,25(suppl_1):S38-45.DOI:10.1093/jtm/tay013. [31]HAN Y,LENG Y X,YAO G Q.Effects of antibiotics on intestinal microflora and intestinal mucosal barrier function and its mechanisms[J].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,2017,29(11):1047-1051.DOI:10.3760/cma.j.issn.2095-4352.2017.11.019. [32]DIETRICH C G,KOTTMANN T,ALAVI M.Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea[J].World J Gastroenterol,2014,20(42):15837-15844.DOI:10.3748/wjg.v20.i42.15837. [33]ALLEN S J,WAREHAM K,WANG D,et al.A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital:a multicentre,randomised,double-blind,placebo-controlled,parallel arm trial(PLACIDE)[J].Health Technol Assess,2013,17(57):1-140.DOI:10.3310/hta17570. [34]MCFARLAND L V,OZEN M,DINLEYICI E C,et al.Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections[J].World J Gastroenterol,2016,22(11):3078-3104.DOI:10.3748/wjg.v22.i11.3078. [35]AGAMENNONE V,KRUL C A M,RIJKERS G,et al.A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands[J].BMC Gastroenterol,2018,18(1):103.DOI:10.1186/s12876-018-0831-x. [36]CAI J Y,ZHAO C Y,DU Y J,et al.Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea:systematic review with network meta-analysis[J].United European Gastroenterol J,2018,6(2):169-180.DOI:10.1177/2050640617736987. [37]ZHANG D M,XU B B,YU L,et al.A prospective control study of Saccharomyces Boulardii in prevention of antibiotic-associated diarrhea in the older inpatients[J].Zhonghua Nei Ke Za Zhi,2017,56(6):398-401.DOI:10.3760/cma.j.issn.0578-1426.2017.06.003. [38]WAN C M,YU H,LIU G,et al.A multicenter randomized controlled study of Saccharomyces Boulardii in the prevention of antibiotic-associated diarrhea in infants and Young children[J].Chinese Journal of Pediatrics,2017,55(5):349-354.DOI:10.3760/cma.j.issn.0578-1310.2017.05.008. [39]BLAABJERG S,ARTZI D M,AABENHUS R.Probiotics for the prevention of antibiotic-associated diarrhea in outpatients——a systematic review and meta-analysis[J].Antibiotics(Basel),2017,6(4):E21.DOI:10.3390/antibiotics6040021. [40]HAYES S R,VARGAS A J.Probiotics for the prevention of pediatric antibiotic-associated diarrhea[J].Explore(NY),2016,12(6):463-466.DOI:10.1016/j.explore.2016.08.015. [41]SZAJEWSKA H,KOLODZIEJ M.Systematic review with meta-analysis:saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea[J].Aliment Pharmacol Ther,2015,42(7):793-801.DOI:10.1111/apt.13344. [42]SZAJEWSKA H,CANANI R B,GUARINO A,et al.Probiotics for the prevention of antibiotic-associated diarrhea in children[J].J Pediatr Gastroenterol Nutr,2016,62(3):495-506.DOI:10.1097/MPG.0000000000001081. [43]EHRHARDT S,GUO N,HINZ R,et al.Saccharomyces boulardii to prevent antibiotic-associated diarrhea:a randomized,double-masked,placebo-controlled trial[J].Open Forum Infect Dis,2016,3(1):ofw011.DOI:10.1093/ofid/ofw011. [44]VERNAYA M,MCADAM J,HAMPTON M D.Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients:a systematic review[J].JBI Database System Rev Implement Rep,2017,15(1):140-164.DOI:10.11124/JBISRIR-2016-003234. [45]JAFARNEJAD S,SHAB-BIDAR S,SPEAKMAN J R,et al.Probiotics reduce the risk of antibiotic-associated diarrhea in adults(18-64 years)but not the elderly(>65 years):a meta-analysis[J].Nutr Clin Pract,2016,31(4):502-513.DOI:10.1177/0884533616639399. [46]XIE C,LI J,WANG K,et al.Probiotics for the prevention of antibiotic-associated diarrhoea in older patients:a systematic review[J].Travel Med Infect Dis,2015,13(2):128-134.DOI:10.1016/j.tmaid.2015.03.001. [47]WRIGHT K,WRIGHT H,MURRAY M.Probiotic treatment for the prevention of antibiotic-associated diarrhoea in geriatric patients:a multicentre randomised controlled pilot study[J].Australas J Ageing,2015,34(1):38-42.DOI:10.1111/ajag.12116. [48]LACY B E.Review article:an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome[J].Aliment Pharmacol Ther,2018,48(8):817-830.DOI:10.1111/apt.14948. [49]ISHAQUE S M,KHOSRUZZAMAN S M,AHMED D S,et al.A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation(Bio-Kult?)in the management of diarrhea-predominant irritable bowel syndrome[J].BMC Gastroenterol,2018,18(1):71.DOI:10.1186/s12876-018-0788-9. [50]HAN K,WANG J,SEO J G,et al.Efficacy of double-coated probiotics for irritable bowel syndrome:a randomized double-blind controlled trial[J].J Gastroenterol,2017,52(4):432-443.DOI:10.1007/s00535-016-1224-y. [51]YOON H,PARK Y S,LEE D H,et al.Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome:a randomized,double-blind,placebo-controlled trial[J].J Clin Biochem Nutr,2015,57(2):129-134.DOI:10.3164/jcbn.15-14. [52]STAUDACHER H M,WHELAN K.Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet:probiotics,prebiotics and the low FODMAP diet[J].Proc Nutr Soc,2016,75(3):306-318.DOI:10.1017/S0029665116000021. [53]SUN Y Y,LI M,LI Y Y,et al.The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome:a randomized,double-blind,placebo-controlled trial[J].Sci Rep,2018,8(1):2964.DOI:10.1038/s41598-018-21241-z. [54]SHIN S P,CHOI Y M,KIM W H,et al.A double blind,placebo-controlled,randomized clinical trial that breast milk derived-Lactobacillus Gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome[J].J Clin Biochem Nutr,2018,62(2):179-186.DOI:10.3164/jcbn.17-73. [55]ABBAS Z,YAKOOB J,JAFRI W,et al.Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome:a randomized trial[J].Eur J Gastroenterol Hepatol,2014,26(6):630-639.DOI:10.1097/MEG.0000000000000094. [56]FORD A C,QUIGLEY E M,LACY B E,et al.Efficacy of prebiotics,probiotics,and synbiotics in irritable bowel syndrome and chronic idiopathic constipation:systematic review and meta-analysis[J].Am J Gastroenterol,2014,109(10):1547-1561;quiz 1546,1562.DOI:10.1038/ajg.2014.202. [57]ZHANG Y,LI L X,GUO C G,et al.Effects of probiotic type,dose and treatment duration on irritable bowel syndrome diagnosed by Rome Ⅲ criteria:a meta-analysis[J].BMC Gastroenterol,2016,16(1):62.DOI:10.1186/s12876-016-0470-z. [58]HOD K,SPERBER A D,RON Y,et al.A double-blind,placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS[J].Neurogastroenterol Motil,2017,29(7).[Epub ahead of print].DOI:10.1111/nmo.13037. [59]GANJI-ARJENAKI M,RAFIEIAN-KOPAEI M.Probiotics are a good choice in remission of inflammatory bowel diseases:a meta analysis and systematic review[J].J Cell Physiol,2018,233(3):2091-2103.DOI:10.1002/jcp.25911. [60]DURCHSCHEIN F,PETRITSCH W,HAMMER H F.Diet therapy for inflammatory bowel diseases:the established and the new[J].World J Gastroenterol,2016,22(7):2179-2194.DOI:10.3748/wjg.v22.i7.2179. [61]DERWA Y,GRACIE D J,HAMLIN P J,et al.Systematic review with meta-analysis:the efficacy of probiotics in inflammatory bowel disease[J].Aliment Pharmacol Ther,2017,46(4):389-400.DOI:10.1111/apt.14203. [62]DIGNASS A,LINDSAY J O,STURM A,et al.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2:current management[J].J Crohns Colitis,2012,6(10):991-1030.DOI:10.1016/j.crohns.2012.09.002. [63]LOSURDO G,IANNONE A,CONTALDO A,et al.Escherichia coli nissle 1917 in ulcerative colitis treatment:systematic review and meta-analysis[J].J Gastrointestin Liver Dis,2015,24(4):499-505.DOI:10.15403/jgld.2014.1121.244.ecn. [64]SHEN J,ZUO Z X,MAO A P.Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis,Crohn's disease,and pouchitis:meta-analysis of randomized controlled trials[J].Inflamm Bowel Dis,2014,20(1):21-35.DOI:10.1097/01.MIB.0000437495.30052.be. [65]TAMAKI H,NAKASE H,INOUE S,et al.Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis:a randomized,double-blinded,placebo-controlled multicenter trial[J].Dig Endosc,2016,28(1):67-74.DOI:10.1111/den.12553. [66]YOSHIMATSU Y,YAMADA A,FURUKAWA R,et al.Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis[J].World J Gastroenterol,2015,21(19):5985-5994.DOI:10.3748/wjg.v21.i19.5985. [67]PALUMBO V D,ROMEO M,MARINO GAMMAZZA A,et al.The long-term effects of probiotics in the therapy of ulcerative colitis:a clinical study[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2016,160(3):372-377.DOI:10.5507/bp.2016.044. [68]THOMSEN M,CLARKE S,VITETTA L.The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments[J].Benef Microbes,2018:1-18.DOI:10.3920/BM2017.0172. [69]WEI D,HEUS P,VAN DE WETERING F T,et al.Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer[J].Cochrane Database Syst Rev,2018,8:CD008831.DOI:10.1002/14651858.CD008831.pub3. [70]LINN Y H,THU K K,WIN N H H.Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients:a randomized double-blind placebo-controlled study[J].Probiotics Antimicrob Proteins,2018.[Epub ahead of print].DOI:10.1007/s12602-018-9408-9. [71]DEMERS M,DAGNAULT A,DESJARDINS J.A randomized double-blind controlled trial:impact of probiotics on diarrhea in patients treated with pelvic radiation[J].Clin Nutr,2014,33(5):761-767.DOI:10.1016/j.clnu.2013.10.015. [72]LIU M M,LI S T,SHU Y,et al.Probiotics for prevention of radiation-induced diarrhea:a meta-analysis of randomized controlled trials[J].PLoS One,2017,12(6):e0178870.DOI:10.1371/journal.pone.0178870. [73]WANG Y H,YAO N,WEI K K,et al.The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer:a systematic review and meta-analysis[J].Eur J Clin Nutr,2016,70(11):1246-1253.DOI:10.1038/ejcn.2016.102. [74]WARDILL H R,VAN SEBILLE Y Z A,CIORBA M A,et al.Prophylactic probiotics for cancer therapy-induced diarrhoea:a meta-analysis[J].Curr Opin Support Palliat Care,2018,12(2):187-197.DOI:10.1097/SPC.0000000000000338. [75]SHIMIZU K,OGURA H,KABATA D,et al.Association of prophylactic synbiotics with reduction in diarrhea and pneumonia in mechanically ventilated critically ill patients:a propensity score analysis[J].J Infect Chemother,2018,24(10):795-801.DOI:10.1016/j.jiac.2018.06.006. [76]CULPEPPER T,CHRISTMAN M C,NIEVES C Jr,et al.Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress:a secondary analysis of a randomised trial[J].Benef Microbes,2016,7(3):327-336.DOI:10.3920/BM2015.0156. [77]ZHAO R,WANG Y,HUANG Y Q,et al.Effects of fiber and probiotics on diarrhea associated with enteral nutrition in gastric cancer patients:a prospective randomized and controlled trial[J].Medicine(Baltimore),2017,96(43):e8418.DOI:10.1097/MD.0000000000008418. [78]DE CASTRO SOARES G G,MARINHO C H,PITOL R,et al.Sporulated Bacillus as alternative treatment for diarrhea of hospitalized adult patients under enteral nutrition:a pilot randomized controlled study[J].Clin Nutr ESPEN,2017,22:13-18.DOI:10.1016/j.clnesp.2017.08.006. [79]PANIGRAHI P,PARIDA S,PRADHAN L,et al.Long-term colonization of a Lactobacillus plantarum synbiotic preparation in the neonatal gut[J].J Pediatr Gastroenterol Nutr,2008,47(1):45-53.DOI:10.1097/MPG.0b013e31815a5f2c. [80]MU?OZ P,BOUZA E,CUENCA-ESTRELLA M,et al.Saccharomyces cerevisiae fungemia:an emerging infectious disease[J].Clin Infect Dis,2005,40(11):1625-1634.DOI:10.1086/429916. [81]SALMINEN M K,RAUTELIN H,TYNKKYNEN S,et al.Lactobacillus bacteremia,clinical significance,and patient outcome,with special focus on probiotic L.rhamnosus GG[J].Clin Infect Dis,2004,38(1):62-69.DOI:10.1086/380455. [82]孙雯娟,张波,李大魁,等.益生菌制剂的发展现状与临床应用进展[J].中国医院药学杂志,2015,35(9):850-857.DOI:10.13286/j.cnki.chinhosppharmacyj.2015.09.22. SUN W J,ZHANG B,LI D K,et al.Development status and clinical application progress of probiotic preparations[J].Chinese Journal of Hospital Pharmacy,2015,35(9):850-857.DOI:10.13286/j.cnki.chinhosppharmacyj.2015.09.22. [83]HUNGIN A P S,MITCHELL C R,WHORWELL P,et al.Systematic review:probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus[J].Aliment Pharmacol Ther,2018,47(8):1054-1070.DOI:10.1111/apt.14539. |
[1] | PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703. |
[2] | HU Jiayan, LYU Mi, WANG Fengyun. The Exploration of the Effects and Mechanisms of Antibiotics on Irritable Bowel Syndrome [J]. Chinese General Practice, 2023, 26(21): 2666-2672. |
[3] | HOU Yujun, ZHAO Ying, JIANG Huiling, TAN Yu, ZHANG Wei, LI Ying, ZHENG Qianhua. Detection and Evaluation Methods of Visceral Sensitivity in Irritable Bowel Syndrome: a Review of the Latest Developments [J]. Chinese General Practice, 2023, 26(21): 2673-2677. |
[4] | SU Haixia, FU Zhaoyuan, GAO Yongze, YU Rongrong, ZHONG Jianchun. Correlation between 5-HT and Diarrhea-type Irritable Bowel Syndrome and Regulation by Traditional Chinese Medicine [J]. Chinese General Practice, 2023, 26(21): 2678-2685. |
[5] | WU Xiaoyu, WAN Chonghua, CHEN Ying, RUAN Yanqin, WENG Yijie, XU Xiaojiang. A Review of Studies on Patient-reported Outcomes and Disease-specific Health-related Quality of Life Instruments for Irritable Bowel Syndrome [J]. Chinese General Practice, 2023, 26(18): 2268-2276. |
[6] | QIN Yuning, ZHAO Tianyi, LIU Fengbin, WANG Xin, CAO Xue, SUN Minglin, LAI Keyun, DI Luyao, GE Zhishan, LIU Song, XING Ying, YANG Lei, YUE Lihong, ZOU Meimei, HE Liyun, LI Hongjiao. Research of the Measurement Properties of the Chinese Version of the Gastrointestinal Symptom Rating Scale for Patients with Gastrointestinal Diseases [J]. Chinese General Practice, 2023, 26(18): 2277-2285. |
[7] | ZHANG Jindong, ZHENG Haonan, ZHANG Tao, DUAN Liping. Effect of Microbiota-targeted Therapy on Gut Microbiota in Patients with Irritable Bowel Syndrome: a Scoping Review [J]. Chinese General Practice, 2023, 26(12): 1520-1529. |
[8] | WANG Kekai, YANG Yanlin, ZHOU Yanni, XIAO Jin, XIE Xin, WU Qinping, CHEN Min. Efficacies of Tong-Xie-Yao-Fang Disassembled Recipes on Brain-gut Peptideina Rat Model of Diarrhea-predominant Irritable Bowel Syndrome [J]. Chinese General Practice, 2023, 26(05): 569-575. |
[9] | Pengning WU, Shuai XIONG, Xiaohan JIANG, Yi ZHANG, Chao LIANG, Min CHEN. Research Progress of Traditional Chinese and Western Medicine in the Treatment of Irritable Bowel Syndrome Based on 5-hydroxytryptamine [J]. Chinese General Practice, 2022, 25(15): 1800-1806. |
[10] | Min CHEN, Xin XIE, Yunzhou SHI, Hui ZHENG, Qiaofeng WU, Haiyan ZHOU, Zhigang LI, Shuguang YU. Research Status and Thoughts on the Comparative Effect of Traditional Chinese Medicine in the Treatment of IBS-D [J]. Chinese General Practice, 2022, 25(15): 1795-1800,F01. |
[11] | Hongyu HUANG, Tiantian LEI, Hongsheng MA, Renwei HU, Jinlin YANG. Pyoderma Gangrenosum with Crohn's Disease Presenting as a Giant Foot Ulcer: a Case Report and Literature Review [J]. Chinese General Practice, 2022, 25(15): 1906-1909. |
[12] | Kun YE, Min LEI, Xin XIE, Hui ZHENG, Min CHEN, Shuguang YU. Mechanism of Huangqi Jianzhong Decoction in Treating Diarrhea Predominant Irritable Bowel Syndrome Based on Network Pharmacology and Molecular Docking Technology [J]. Chinese General Practice, 2022, 25(15): 1814-1824. |
[13] | Yunzhou SHI, Hui ZHENG, Min CHEN, Zhigang LI, Shuguang YU. Review of Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome [J]. Chinese General Practice, 2022, 25(15): 1807-1813. |
[14] | Zhanpeng LIU, Xiaozhong YANG, Mengxue CHEN, Menghui ZHANG, Honggang WANG. Clinical Value of Inflammatory Bowel Disease Symptom Inventory in Evaluating the Activity of Inflammatory Bowel Disease [J]. Chinese General Practice, 2022, 25(14): 1713-1718. |
[15] | Mingxiu WANG, Junkai ZHANG, Wei XU, Xiaojie FAN, Fei LI, Guoying DENG. Irritable Bowel Syndrome Prevalence and Influencing Factors in Senior High School Students [J]. Chinese General Practice, 2022, 25(12): 1506-1511. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||